| Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial A Widmark, A Gunnlaugsson, L Beckman, C Thellenberg-Karlsson, ... The Lancet 394 (10196), 385-395, 2019 | 671 | 2019 |
| Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double … IF Tannock, K Fizazi, S Ivanov, CT Karlsson, A Fléchon, I Skoneczna, ... The lancet oncology 14 (8), 760-768, 2013 | 327 | 2013 |
| Haralick texture features from apparent diffusion coefficient (ADC) MRI images depend on imaging and pre-processing parameters P Brynolfsson, D Nilsson, T Torheim, T Asklund, CT Karlsson, J Trygg, ... Scientific reports 7 (1), 4041, 2017 | 173 | 2017 |
| Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled … P Fransson, P Nilsson, A Gunnlaugsson, L Beckman, B Tavelin, ... The Lancet Oncology 22 (2), 235-245, 2021 | 111 | 2021 |
| Dietary intake of phytoestrogens, estrogen receptor‐beta polymorphisms and the risk of prostate cancer M Hedelin, KA Bälter, ET Chang, R Bellocco, Å Klint, JE Johansson, ... The Prostate 66 (14), 1512-1520, 2006 | 104 | 2006 |
| Association between the presence of bacterial 16S RNA in prostate specimens taken during transurethral resection of prostate and subsequent risk of prostate cancer (Sweden) O Alexeyev, J Bergh, I Marklund, C Thellenberg-Karlsson, F Wiklund, ... Cancer Causes & Control 17, 1127-1133, 2006 | 80 | 2006 |
| Estrogen receptor β polymorphism is associated with prostate cancer risk C Thellenberg-Karlsson, S Lindström, B Malmer, F Wiklund, ... Clinical cancer research 12 (6), 1936-1941, 2006 | 78 | 2006 |
| U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden B Glimelius, B Melin, G Enblad, I Alafuzoff, A Beskow, H Ahlström, ... Acta oncologica 57 (2), 187-194, 2018 | 76 | 2018 |
| Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients LA Tjon‐Kon‐Fat, M Lundholm, M Schröder, T Wurdinger, ... The Prostate 78 (1), 48-53, 2018 | 56 | 2018 |
| A phase 2 trial of the effect of antiandrogen therapy on COVID-19 outcome: no evidence of benefit, supported by epidemiology and in vitro data K Welén, E Rosendal, M Gisslén, A Lenman, E Freyhult, ... European urology 81 (3), 285-293, 2022 | 53 | 2022 |
| Extreme hypofractionation versus conventionally fractionated radiotherapy for intermediate risk prostate cancer: early toxicity results from the Scandinavian randomized phase … A Widmark, A Gunnlaugsson, L Beckman, C Thellenberg-Karlsson, ... International Journal of Radiation Oncology, Biology, Physics 96 (5), 938-939, 2016 | 52 | 2016 |
| Breast cancer as a second primary in patients with prostate cancer—estrogen treatment or association with family history of cancer? CT Karlsson, B Malmer, F Wiklund, H Grönberg The Journal of urology 176 (2), 538-543, 2006 | 43 | 2006 |
| Imaging for the detection of locoregional recurrences in biochemical progression after radical prostatectomy—a systematic review K Sandgren, P Westerlinck, JH Jonsson, L Blomqvist, CT Karlsson, ... European urology focus 5 (4), 550-560, 2019 | 41 | 2019 |
| Quantifying the effect of 3T magnetic resonance imaging residual system distortions and patient-induced susceptibility distortions on radiation therapy treatment planning for … M Adjeiwaah, M Bylund, JA Lundman, CT Karlsson, JH Jonsson, ... International Journal of Radiation Oncology* Biology* Physics 100 (2), 317-324, 2018 | 39 | 2018 |
| Change in prostate volume during extreme hypo-fractionation analysed with MRI A Gunnlaugsson, E Kjellén, O Hagberg, C Thellenberg-Karlsson, ... Radiation Oncology 9, 1-6, 2014 | 38 | 2014 |
| Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP). F Saad, D Keizman, JM O'Sullivan, J Carles, M Wirth, S Gillessen, ... Journal of Clinical Oncology 34 (15_suppl), 5082-5082, 2016 | 36 | 2016 |
| Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases O Sartor, D Heinrich, N Mariados, MJM Vidal, D Keizman, CT Karlsson, ... Annals of Oncology 28 (10), 2464-2471, 2017 | 33 | 2017 |
| Toxicity in patients receiving adjuvant docetaxel+ hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of … PL Kellokumpu-Lehtinen, M Hjälm-Eriksson, C Thellenberg-Karlsson, ... Prostate cancer and prostatic diseases 15 (3), 303-307, 2012 | 33 | 2012 |
| Bone scan index as an imaging biomarker in metastatic castration-resistant prostate Cancer: a multicentre study based on patients treated with Abiraterone acetate (Zytiga) in … M Reza, M Ohlsson, R Kaboteh, A Anand, I Franck-Lissbrant, JE Damber, ... European Urology Focus 2 (5), 540-546, 2016 | 31 | 2016 |
| Prospective randomized trial comparing external beam radiotherapy versus watchful waiting in early prostate cancer (T1b-T2, pN0, grade 1-2, M0) A Widmark, R Tomic, H Modig, C Thellenberg Karlsson, F Lundbeck, ... 53rd annual ASTRO meeting, 2-6, 2011 | 30 | 2011 |
